

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION N	Ю.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/054,727		11/13/2001	Ronald James Ogilvie	PCS10946A	3580
23913	7590	11/19/2003		EXAMINER	
PFIZER		erd der	SMALL, ANDREA D SOUZA		
5TH FLC			ART UNIT	PAPER NUMBER	
NEW YO	ORK, NY	10017-5612	1626		
				DATE MAILED: 11/19/2003	3

Please find below and/or attached an Office communication concerning this application or proceeding.

		Amili	notion N	Applicant/s)				
		Арри	cation N .	Applicant(s)				
	Office Action Summary		64,727 		OGILVIE, RONALD JAMES			
Office Action Summary			iner	Art Unit				
	The MAILING DATE of this commu		a D Small	1626	Ideas			
Period fo		micauon app ars or	Title Cover Sile (1	with the correspondence	iaress			
THE - External after of the control	MAILING DATE OF THIS COMMUL ensions of time may be available under the provision of SIX (6) MONTHS from the mailing date of this core period for reply specified above is less than thirty of period for reply is specified above, the maximum ure to reply within the set or extended period for regrey reply received by the Office later than three month ed patent term adjustment. See 37 CFR 1.704(b).	NICATION. Ins of 37 CFR 1.136(a). In remunication. (30) days, a reply within the statutory period will apply a ply will, by statute, cause the	e statutory minimum of the nd will expire SIX (6) MC application to become a	a reply be timely filed nirty (30) days will be considered timel DNTHS from the mailing date of this c ABANDONED (35 U.S.C. § 133).				
1)🖂	Responsive to communication(s) f	iled on 06 August 2	<u>003</u> .					
	This action is FINAL .	2b) ☐ This action i						
3)[Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims		•					
5)□ 6)⊠ 7)□	Claim(s) <u>19-28</u> is/are pending in the 4a) Of the above claim(s) is/are allowed. Claim(s) <u>19-28</u> is/are rejected. Claim(s) <u>is/are objected to.</u> Claim(s) is/are object to restr	are withdrawn from						
	ion Papers		,					
9)[The specification is objected to by t	he Examiner.						
10)[The drawing(s) filed on is/ard	e: a) accepted o	r b)□ objected to	by the Examiner.				
	Applicant may not request that any obj	ection to the drawing	s) be held in abeya	ince. See 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including							
	The oath or declaration is objected	to by the Examiner.	Note the attache	ed Office Action or form PT	O-152.			
	under 35 U.S.C. §§ 119 and 120							
a) * § 13)⊠ A s 3	Acknowledgment is made of a clair All b) Some * c) None of: 1. Certified copies of the priorit 2. Certified copies of the priorit 3. Copies of the certified copies application from the Internation see the attached detailed Office action acknowledgment is made of a claim ince a specific reference was includ 7 CFR 1.78.	y documents have to y documents have to sof the priority documents fonal Bureau (PCT I fon for a list of the co- for domestic priority ed in the first sente	peen received. Deen received in a Deen received in	Application No n received in this National t received. § 119(e) (to a provisional cation or in an Application	application)			
) The translation of the foreign la				n nna=!#:			
re	Acknowledgment is made of a claim eference was included in the first se	ntence of the specif	/ under 35 U.S.C lication or in an A	. 99 120 and/or 121 since pplication Data Sheet. 37	a specific CFR 1.78.			
Attachmen	t(s)							
1) 🔯 Notic 2) 🔲 Notic	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (Summary (PTO-413) Paper No(s				
	mation Disclosure Statement(s) (PTO-1449)		6) Dother:		•			

Application/Control Number: 10/054,727 Page 2

Art Unit: 1626

DETAILED ACTION

I. Preliminary Matters:

(a) Applicants response filed 8/6/2003 has been received and entered into the file.

-Claims 1-18 have been cancelled.

-Claims 24-28 have been newly added.

-claims 19-28 are instantly pending.

II. Remarks:

(a) Issues regarding 35 USC 102(b): The rejections cited against claims 19-23 have been overcome due to the amendments made to said claims. However, the amendments have resulted in a new ground of rejection which is outlined below.

III. New Rejections:

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(a) Claims 24-28 are rejected under 35 U.S.C. 102(b) as being anticipated by Macor, et al (US 5,545,644).

Applicants claims relate to eletriptan and its acid addition salt (hydrobrimide) 'substantially free' (this reads on an amount >0) of a dimer of eletriptan precursor (the process of making this compound does not lend patentable weight to the claim as the claim is drawn to a product claim). Macor, et al teach eletriptan and its acid addition salt (hydrobromide). See col.

2, lines 55-68. The reference also teaches a process of making the same. See col. 49, examples 32-34. The chemical compounds recited in the reference are prepared from the same precursor that is prone to forming the dimer and hence would result in the product that has an amount (>0) of dimer in the end product as is instantly claimed. Hence, the reference anticipates the instant claims.

(b) Claims 19-23 are rejected under 35 U.S.C. 102(b) as being anticipated by Willems, et al (cited by Applicants) OR Harding, et al (US 6,110,940) cited by Examiner.

Applicants claims relate to eletriptan or its commercially available hydrobromide salt that is 'free' of a dimer of eletriptan precursor, which reads on eletriptan or its hydrobromide salt by itself. Willems, et al teach eletriptan and Harding, et al teach its acid addition salt (hydrobromide). See page 213, figure 1, depiction of Eletriptan (Willems reference) and abstract (Harding reference). Hence, these references anticipate the instant claims.

IV. Finality:

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Application/Control Number: 10/054,727 Page 4

Art Unit: 1626

however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

V. Contact Information:

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrea D. Small, whose telephone number is (703) 305-0811. The examiner can normally be reached on Monday-Thursday from 8:30 AM - 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K. McKane, can be reached at (703) 308-4537. The Unofficial fax phone number for this Group is (703) 308-7921. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [Joseph.McKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-1234

Andrea D. Small, Esq. November 14, 2003

Joseph K. McKane Supervisory Patent Examiner

Joseph K. M. Kans

Art Unit 1626

Technology Center 1